Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Balagopalan Nair (NPI 1063494953)

Field	Value
Entity Type	Individual
Organization	Balagopalan Nair
Address	8901 Carti Way
City	Little Rock
State	AR
ZIP	72205
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	November 16, 2005

Payer Source	Total Paid
Medicare	$4.1M
Medicaid	$0

Key Findings

BALAGOPALAN NAIR is a Hematology & Oncology Physician in LITTLE ROCK, AR whose Medicare billing profile is dominated by high-cost oncology biologics and infusion therapies; the top code J9271 (pembrolizumab) alone accounts for $1.9M in revenue (47.4% of this provider's total Medicare revenue) and shows 43.4K claims, indicating a practice organized around high-volume immunotherapy administration. The presence of other oncology drugs such as Q5126 (bevacizumab biosimilar) and J9264 (paclitaxel protein-bound particles) alongside chemotherapy administration CPTs supports an infusion-centric outpatient oncology model.

Revenue concentration is unusually high: the precomputed top 3 Medicare codes by revenue (J9271, J1437, J1569) account for 60.7% of this provider's total Medicare revenue, with J1437 contributing $270.3K (6.9%) and J1569 contributing $254.1K (6.4%). This level of concentration around a few injectable biologics signals dependency on a narrow set of high-revenue therapies for Medicare income.

This provider reports Total Medicare revenue of $4.1M and has no Medicaid billing on file, so payer mix is effectively single-payer at the claims level (Medicare-only). The absence of any Medicaid billing on file (none below) increases exposure to Medicare policy and rate changes for the entire revenue base.

Competitive standing on specific drugs is strong at the national level: J9271 ranks #22 of 1841 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code) and J1437 ranks #7 of 581 providers nationally (99th percentile; extreme outlier). These ranks identify the provider as a major national outlier for specific high-cost injectable products rather than a modest local participant for those therapies.

Administration and infusion intensity is evident in procedural codes: 96413 (chemotherapy administration) shows $97.8K revenue and ranks #49 of 7514 providers nationally (99th percentile; extreme outlier), 96417 ranks #7 of 3014 providers nationally (100th percentile; extreme outlier), and 96411 ranks #4 of 1354 providers nationally (100th percentile; extreme outlier). The combination of frequent drug injections and add-on infusion codes indicates sustained throughput of multi-agent chemo/biologic regimens in-office.

The provider also bills a mix of supportive-care injectable drugs consistent with an oncology practice managing treatment side effects: J0885 (epoetin alfa) appears with 14.8K claims and $88.8K revenue (2.3%), ranking #49 of 953 providers nationally (95th percentile; notably above typical national volume), and J2506 (pegfilgrastim) contributes $75.7K (1.9%) and ranks #32 of 586 providers nationally (95th percentile). These supportive therapies, together with immune globulin J1569 ($254.1K, 6.4%), point to integrated management of anemia, neutropenia, and immune-modulating needs.

High outpatient evaluation-and-management volume complements the infusion work: 99214 has 1.6K claims, $138.7K revenue (3.5%) and ranks #3031 of 479517 providers nationally (99th percentile; extreme outlier), while 99213 has 1.4K claims and $76.3K revenue (1.9%) and ranks #2727 of 457151 providers nationally (99th percentile; extreme outlier). These elevated E/M ranks indicate the practice not only administers infusions but also maintains substantial clinic visit throughput for follow-up and complex management.

The NPI was enumerated on 2005-11-16 (~21 years ago), indicating long tenure in the Medicare program. Combined with multiple 99th–100th percentile national ranks and concentrated biologic revenue, this suggests an established, high-volume oncology infusion practice with sustained Medicare reliance and little to no Medicaid presence.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

88 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	43,400	$40	$1.9M
J1437	Injection, ferric derisomaltose, 10 mg	15,900	$20	$270.3K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	7,260	$40	$254.1K
Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg	3,930	$60	$220K
J0897	Injection, denosumab, 1 mg	10,980	$20	$197.6K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	4,390	$30	$149.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,590	$90	$138.7K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	13,500	$10	$135K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	870	$120	$108.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,120	$90	$97.8K

Showing 1–10 of 88

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 88 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Balagopalan Nair — 17 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

88 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	40	20,700	$40	$896.3K
Q5126	3	10	3,210	$60	$174.1K
J1569	3	10	2,560	$40	$120.3K
J1437	1	20	6,450	$20	$107.8K
J9264	2	10	9,300	$10	$96.2K
Q5115	1	20	2,800	$30	$95.9K
J0897	20	160	2,580	$20	$89.7K
J2506	1	10	580	$80	$40.4K
J0885	5	40	4,070	$10	$38K
96413	4	80	380	$90	$36.6K

Showing 1–10 of 88

Related Providers

Other providers that share a Tax Identification Number (TIN) with Balagopalan Nair, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Central Arkansas Radiation Therapy Institute Inc	AR	Hematology & Oncology Physician	$0	$11M
Central Arkansas Radiation Therapy Institute Inc	AR	Radiation Oncology Physician	$6.7M	$3.6M
Kamal Patel	AR	Hematology & Oncology Physician	$5.7M	$0
James Keane	AR	Procedural Dermatology Physician	$4.9M	$0
Ryan Hall	AR	Hematology & Oncology Physician	$4.6M	$0
Harshivinderjit Bains	TX	Ophthalmology Physician	$4.1M	$0
Amar Patel	TX	Ophthalmology Physician	$3.8M	$0
Thomas Bochow	TX	Ophthalmology Physician	$3.6M	$0
Richard Kinsey	TN	Anatomic Pathology & Clinical Pathology Physician	$3.3M	$147.3K
Lawrence Mendelsohn	AR	Hematology & Oncology Physician	$3.4M	$0

Nearby Providers

Other providers in the same ZIP code as Balagopalan Nair, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
University Of Arkansas For Medical Sciences	AR	General Acute Care Hospital	$0	$87.2M
University Of Arkansas For Medical Sciences	AR	Internal Medicine Physician	$0	$28.6M
University Of Arkansas For Medical Sciences	AR	Pediatrics Physician	$0	$27.6M
Arkansas Department Of Health Immunizations	AR	Public Health or Welfare Agency	$0	$19.3M
Baptist Health	AR	General Acute Care Hospital	$0	$16.4M
Arkansas Department Of Health Family Planning Clinic	AR	Public Health or Welfare Agency	$0	$15.6M
Pediatrix Medical Group Of Arkansas PA	AR	Neonatal-Perinatal Medicine Physician	$0	$14.6M
Chenal Family Therapy, Plc	AR	Mental Health Counselor	$0	$12.2M
Francis A. Allen School For Exceptional Children, Inc.	AR	Developmentally Disabled Services Day Training Agency	$0	$11.9M
Arkansas Department Of Health Std	AR	Public Health or Welfare Agency	$0	$8.4M

Balagopalan Nair — Billing Profile & Reimbursement Data

Sign up for Balagopalan Nair — Billing Profile & Reimbursement Data policy alerts

Balagopalan Nair — Billing Profile & Reimbursement Data

Sign up for Balagopalan Nair — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References